 |
Frontiers in Multiple Sclerosis: New and Emerging Therapies CME/CE Authors: Bruce A. Cohen, MD; Bruce Cree, MD, PhD, MCR; Clyde E. Markowitz, MD; Patricia K. Coyle, MDAuthor Information and Disclosures Release Date: June 9, 2008; Valid for credit through August 31, 2008 | Physicians - maximum of 1.75 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.7 ANCC contact hours | | This online activity is based on presentations at the CME/CE symposium titled "Frontiers in Multiple Sclerosis: New and Emerging Therapies" on Thursday, May 31, 2007, at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Washington, DC. Persons in attendance at the symposium are NOT eligible for AMA PRA Category 1 Credit™ for completing this enduring material. The CMSC has reviewed and approved this report as appropriate for presentation as a spin-off of an Industry Supported Symposium. The report reflects the content and views of the sponsor and is not part of the official CMSC Annual Meeting program. This activity has been approved for AMA PRA Category 1 Credit™.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medical Education Collaborative, Inc. |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Discuss the rationale and mechanisms of action of novel treatment options for MS;
- Review the relation of new therapy options to the role of B and T cells in MS
pathogenesis;
- Describe the potential clinical place of novel therapies in MS treatment and approaches to patient selection;
- Summarize the benefits of combined, sequential, and multitargeted therapies for MS.
Author Disclosures Bruce A. Cohen, MD
Disclosure: Sources of Funding for Research: Biogen Idec; EMD Serono, Inc; Novartis Pharmaceuticals Corp
Consulting Agreements: Bayer HealthCare Pharmaceuticals Inc; Biogen Idec; Novartis Pharmaceuticals Corp; Pfizer Inc; EMD Serono, Inc; Teva Neuroscience, Inc
Speakers' Bureau/Honorarium Agreements: Bayer HealthCare Pharmaceuticals Inc; EMD Serono, Inc; Pfizer Inc; Teva Neuroscience,
Inc
Financial Interests/Stock Ownership: Abbott Laboratories; CVS/Caremark
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Bruce Cree, MD, PhD, MCR
Disclosure: Sources of Funding for Research: Genentech, Inc
Consulting Agreements: Genentech, Inc
Speakers' Bureau/Honorarium
Agreements: Biogen Idec; EMD Serono, Inc; Teva Neuroscience, Inc
Financial Interests/Stock Ownership: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: Cladribine; fingolimod; fumarate; laquinimod; teriflunomide
Clyde E. Markowitz, MD
Disclosure: Sources of Funding for Research: Bayer HealthCare Pharmaceuticals Inc; Biogen
Idec; BioMS Medical Corp; EMD Serono, Inc; Genentech, Inc; Opexa Therapeutics; PDL BioPharma, Inc; Pfizer Inc; Teva Neuroscience, Inc
Consulting Agreements: HealthCare Pharmaceuticals Inc; Biogen Idec; BioMS Medical Corp; EMD Serono, Inc; Genentech, Inc; Teva Neuroscience, Inc
Speakers' Bureau/Honorarium Agreements: Bayer HealthCare Pharmaceuticals Inc, Biogen Idec; EMD Serono, Inc; Genentech, Inc; Pfizer Inc; Teva
Neuroscience, Inc
Financial Interests/Stock Ownership: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Patricia K. Coyle, MD
Disclosure: Sources of Funding for Research: Bayer HealthCare Pharmaceuticals Inc.; EMD Serono, Inc; Teva Neuroscience, Inc
Consulting Agreements: Bayer HealthCare
Pharmaceuticals Inc.; EMD Serono, Inc; Teva Neuroscience, Inc
Speakers' Bureau/Honorarium Agreements: Bayer HealthCare Pharmaceuticals Inc.; EMD Serono, Inc; Teva Neuroscience, Inc
Financial Interests/Stock Ownership: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
|
 |
This program is sponsored by MEC. This activity was developed in collaboration with Medical Education Collaborative and the Discovery Institute of Medical Education, New York Office Medical Education Collaborative, Inc. (MEC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
MEC designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
MEC is the accredited provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. RNs, LPNs, LVNs, and NPs can receive up to 1.7 contact hours for participation in this program. Provider approved by the California Board of Registered Nursing, Provider Number CEP 12990, for 2.0 contact hour(s). For questions concerning credit in the state of California
please contact MEC online at www.meccme.org or by phone at 303-420-3252.
Contact This Provider
|
|
